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Abstract (195 words) 
 
Fibroblast growth factor 21 (FGF21) is increasingly recognized as an important metabolic 
regulator of glucose homeostasis. Here, we conducted an exome-chip association analysis by 
genotyping 5169 Chinese individuals from a community-based cohort and two clinic-based 
cohorts. A custom Asian Exome-chip was used to detect genetic determinants influencing 
circulating FGF21 levels. Single-variant association analysis interrogating 70,444 single 
nucleotide polymorphisms identified a novel locus, GCKR, significantly associated with 
circulating FGF21 levels at genome-wide significance. In the combined analysis, the 
common missense variant of GCKR, rs1260326 (p.Pro446Leu), showed an association with 
FGF21 levels after adjustment for age and sex (P=1.61x10
-12
; β[SE]:0.14[0.02]), which 
remained significant on further adjustment for body mass index (P=3.01x10
-14
; 
β[SE]:0.15[0.02]). GCKR Leu446 may influence FGF21 expression via its ability to increase 
glucokinase (GCK) activity. This can lead to enhanced FGF21 expression via elevated fatty 
acid synthesis, consequent to the inhibition of carnitine/palmitoyl-transferase by malonyl-
CoA; and via increased glucose-6-phosphate mediated activation of the carbohydrate 
response element binding protein, known to regulate FGF21 gene expression. Our findings 
shed new light on the genetic regulation of FGF21 levels. Further investigations to dissect the 
relationship between GCKR and FGF21, with respect to the risk of metabolic diseases, are 
warranted.  
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Introduction 
Fibroblast growth factor 21 (FGF21) is a circulating metabolic hormone 
predominantly secreted from the liver and from other tissues, such as adipose tissue, pancreas 
and skeletal muscle (1; 2). Numerous animal studies have demonstrated its favorable effects 
on insulin sensitivity, glucose and lipid metabolism, and body weight, in obese mice and 
diabetic monkeys (1-5). High circulating levels of FGF21, however, have been observed in 
patients with obesity and a range of obesity-related conditions, including type 2 diabetes 
(T2DM), coronary artery disease (CAD) and the metabolic syndrome (MetS) (1). Our group 
previously showed that elevated levels of FGF21 independently predicted the development of 
T2DM (6), carotid atherosclerosis (7), and kidney disease progression in T2DM subjects (8). 
Observations of the paradoxical increase of FGF21 in the above diseases may represent a 
compensatory response to FGF21 resistance, which has been demonstrated in a previous 
study of mice with diet-induced obesity (9), or to combat the metabolic disturbances in these 
disease conditions. 
 
The circulating levels of FGF21 have been reported to be moderately heritable in a 
twin study of young adults, with 40% of variation attributed to genetic determinants (10). So 
far, only a few genetic variants have been reported to show weak associations with 
circulating FGF21 levels (11; 12). No previous genome-wide or exome-wide association 
analyses on circulating FGF21 levels have been published to date. The heritability of 
circulating FGF21 levels remains largely unexplained. This study sought to identify the 
genetic determinants of circulating FGF21 levels. We conducted an exome-chip association 
analysis on circulating FGF21 levels using a specially designed Illumina HumanExome 
BeadChip (Asian Exome-chip) in a Chinese population (13; 14). In consideration of the 
possible difference in circulating FGF21 levels between individuals from the patient groups 
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and those from the general population, possibly due to the intrinsic metabolic stress under 
disease conditions and the treatment effects on FGF21 expression, we first conducted the 
association analysis in a community-based and two clinic-based cohorts separately, followed 
by a combined analysis involving a total of 5169 individuals. 
 
Research Design and Methods 
 
Subjects 
An exome-chip association study on circulating FGF21 levels was performed in 5169 
Chinese individuals who were recruited from the Hong Kong Cardiovascular Risk Factor 
Prevalence Study (CRISPS; n=1172); the Hong Kong West Diabetes Registry (HKWDR; 
n=2884); and the Hong Kong Chinese Coronary Artery Disease (HK-CAD) study (n=1113). 
Details of the study cohorts and measurement of FGF21 levels were described in the 
Supplementary notes.  
 
Genotyping and data quality control  
All subjects were genotyped using the custom Asian Exome-chip (13; 14) with an add-on 
content of 58,317 single nucleotide polymorphisms (SNPs), including a custom panel of over 
30,000 missense or nonsense coding variants on top of the standard content of the Infinium 
HumanExome BeadChip (HumanExome-12v1_A; Illumina, CA). Genotyping of the Exome 
array was performed using the Illumina iScan system platform at the Centre for Genomic 
Sciences of the University of Hong Kong. The GenTrain version 2.0 in GenomeStudio 
V2011.1 (Illumina) was used to perform genotyping calling. Details of genotype quality 
control were described in the Supplementary notes. After all QC measures, a total of 1172 
subjects and 76,389 variants remained in the association analysis of the CRISPS cohort, 
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whilst the analyses of the clinic-based cohorts included a total of 2884 subjects and 77598 
variants from the HKWDR; and 1113 subjects and 75468 variants from the HK-CAD study. 
The combined analysis included only polymorphic SNPs in all three cohorts and had MAF 
≥0.1%, totaling 5169 subjects and 70,444 variants. The P-value informed linkage 
disequilibrium (LD) based clumping approach with the “--clump” command implemented in 
PLINK was performed to address the between-SNP LD. Each index SNP represented the 
strongest association P-value from each clumped region. Each index SNP formed clumps 
with other variants which were within ± 500kb from the index SNP and in LD with the index 
SNP (r
2 
≥0.2).   
 
Statistical analysis 
For each cohort, we carried out single-variant association tests, under the additive genetic 
model, for all markers that passed quality controls using PLINK version 1.9 (15). The FGF21 
levels were first transformed to rank-based inverse normal residuals before analysis to ensure 
normality and minimize the possible effect of outliers. Age, sex and the first 2 principal 
components (PCs) were included as covariates in the multiple linear regression model (Model 
1) (Supplementary Figure 1). To assess adiposity independent association, body mass index 
(BMI) was included as an additional covariate in Model 2. Meta-analysis of the association 
results of the three cohorts was conducted using GWAMA 
(http://www.geenivaramu.ee/en/tools/gwama; accessed 20 Dec 2016) (16). The inverse 
variance fixed-effect method was employed to meta-analyze the summary statistics of the 
three cohorts. The heterogeneity of effect was assessed using Cochran’s Q-test and I
2
 index. 
All 70,444 SNPs showed no evidence of heterogeneity in the combined analysis with a 
Cochran’s Q-test P-value ≥1x10
-6
 (a value selected to take into account the multiple testing 
and the stringent Bonferroni correction) (17). Exome-wide significance was defined as P 
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<7.10x10
-7
 (=0.05/70,444). As visualized in a Quantile-Quantile plot (Figure 1), the test 
statistics appeared well-calibrated. Associations of GCKR rs1260326 with fasting plasma 
glucose (FPG) and triglyceride (TG) were examined by multiple linear regression analyses in 
non-T2DM individuals and in subjects not taking lipid lowering medications, respectively, 
with adjustment for age, sex, BMI, PC1 and PC2. 
 
Results 
Exome-chip association study for circulating FGF21 levels 
Of the 70,444 polymorphic SNPs (Figure 2) examined for associations with circulating 
FGF21 levels in 5169 Chinese individuals (Table 1), 45.06% altered protein composition and 
19.96% were Asian-specific variants with MAF 0.1-5%.  
 
The strongest association was detected at a missense variant rs1260326 (p.Pro446Leu) of 
GCKR (Table 2 and Supplementary Figure 2). The T (Leu446) allele of rs1260326 was 
significantly associated with a higher level of FGF21 levels at genome-wide significance 
(Model 1: Pcombined=1.61x10
-12
; β[SE]: 0.14[0.02]; Pheterogeneity=0.018; I
2
=0.75; Model 2: 
Pcombined=3.01x10
-14
; β[SE]: 0.15[0.02]; Pheterogeneity=0.041; I
2
=0.69; Table 2; Figure 2). GCKR 
rs1260326 was significantly associated with TG (P<0.001; β[SE]:0.08[0.005]). A modest 
association between rs1260326 and FPG (P=0.013; β[SE]:-0.01[0.004]) was also observed. 
The associations between rs1260326 with FGF21 levels remained significant when FPG 
(Pcombined=1.60x10
-14
; β[SE]:0.16[0.02]) or TG (Pcombined=1.26x10
-7
; β[SE]:0.11[0.02]) or both 
(Pcombined=5.42x10
-7
; β[SE]:0.10[0.02]) were included in the adjustment models. The 
proportion of variance in FGF21 levels explained by rs1260326 was estimated to be 0.97%. 
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In the combined analysis, we also observed suggestive associations of an intronic SNP 
rs17817964 at FTO (Pcombined=1.44x10
-6
; β[SE]:0.13[0.03]; Pheterogeneity=0.690; I
2
=0) and a 
missense variant rs2273983 (p.Asn719Ser) at TSR1 (Pcombined=4.61x10
-6
; β[SE]:0.48[0.10]; 
Pheterogeneity=0.590; I
2
=0) with FGF21 levels in adjustment Model 1. The associations of these 
two variants were slightly attenuated on further adjustment for BMI (Table 2). 
Supplementary table 1 shows the 27 index SNPs which showed associations with FGF21 
level at Pcombined <5x10
-4 
in the combined analysis. 
 
Discussion 
The current study reports the first exome-chip association analysis on circulating FGF21 
levels. By genotyping 5169 Chinese individuals using a custom Asian Exome-chip, we 
identified a genome-wide significant association between GCKR rs1260326, a proline to 
leucine substitution at amino acid 446 (p.Pro446Leu), and circulating FGF21 levels. Our 
study has shed light on the possible role of GCKR on the regulation of circulating FGF21 
levels. GCKR, encoding the glucokinase regulator (also known as glucokinase regulatory 
protein [GKRP]), has been implicated in a wide range of important metabolic pathways, such 
as glucose homeostasis and lipid metabolism (18). Both FGF21 and GCKR are highly 
expressed in the liver (1; 18). GCKR acts as a competitive inhibitor of glucokinase (GCK), 
the principal modulator of glucose uptake and release in the liver (18). GCKR forms an 
inhibitory complex with GCK (GCKR-GCK complex), and allosterically controls its activity 
in the presence of fructose. Dissociation of the GCKR-GCK complex facilitates the 
translocation of GCK to cytoplasm where hepatic glycolysis is stimulated (18).  
 
The Pro446 residue of GCKR is conserved across various species, including human and rat. 
GCKR p.Pro446Leu is located in close proximity to Asp413 and Gln443 which form a 
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critical salt bridge with Arg186 of GCK (19). Thus, the variant could interfere directly with 
the binding of GCKR to GCK (19), thereby leading to reduced inhibition of GCK. This in 
turn contributed to an enhanced glycolytic flux and promoted uptake of glucose into the liver. 
Accompanying this increased rate of glycolysis is the raised levels of other liver metabolites, 
such as malonyl-CoA which ultimately lead to enhanced production of TG (20).  This 
explains the reduced FPG and raised TG levels observed in individuals carrying the Leu446 
(T) allele as previously reported by the French longitudinal cohort study DESIR (Data from 
an Epidemiological Study on the Insulin Resistance syndrome) (21) and in the current study. 
GCKR Leu446 may influence FGF21 expression via its ability to increase GCK activity. This 
leads to elevated phosphorylation of glucose to glucose-6-phosphate (G6P) and the 
subsequent inhibition of carnitine/palmitoyl-transferase, the rate limiting enzyme of β-
oxidation, by malonyl-CoA (22). In turn, such changes may result in enhanced FGF21 
expression via increased G6P mediated activation of carbohydrate response element binding 
protein (ChREBP) (23); and via elevated fatty acid synthesis (1), which were known to 
regulate FGF21 gene expression. 
 
GCKR has been recognized as a highly pleiotropic gene (1; 2). Common variants of GCKR, 
including rs1260326 or its intronic proxy SNP rs780094 (r
2
=0.92), have been shown to be 
associated with multiple metabolic traits, including FPG and TG (2; 13; 21). The current 
study further demonstrated that rs1260326 may play a role in the regulation of FGF21 levels 
which is independent from the effect of BMI, FPG and TG. Future functional studies 
elucidating the role of GCKR in the in vivo regulation of FGF21 levels are warranted.  
 
Recent clinical trials have demonstrated that treatments with FGF21 analogs in obese patients 
with T2DM resulted in obvious improved lipid profiles, lowered fasting insulin and body 
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weight, similar to what have been observed in animals (24; 25). In particular, FGF21 
treatment has demonstrated a rapid and prominent reduction in circulating TG, which 
occurred as soon as two days after treatment (24). However, there was lack of significant 
effect on glycemic control in humans (24; 25), contradictory to the glucose lowering effect of 
FGF21 observed in animals (4; 5). In line with these reports, the GCKR rs1260326 was found 
to be strongly associated with TG but only modestly correlated with FPG in the current study 
(24; 25). Taken together, these findings suggest that FGF21 may play a more prominent role 
in regulating lipid metabolism and adiposity, rather than blood glucose. On the other hand, 
our finding that rs1260326 could possibly influence the circulating levels of FGF21 via 
enhanced GCK activity, also suggest that alterations in hepatic carbohydrate metabolism can 
impact on FGF21 expression and its circulating levels.  
 
The major limitation of the current study was the lack of external validations. Further 
replication analysis in independent cohorts in other Asians or European populations would 
serve to validate our findings. The design of the exome-chip has allowed us to examine more 
coding variants with much lower MAF compared to conventional genome-wide association 
studies. However, the relatively small sample size has limited our study power to detect the 
association of rare or low-frequency variants. With a view to achieve a larger sample size, a 
meta-analysis of genome/exome-wide association studies would be useful to identify 
additional genetic variants influencing FGF21 levels. 
 
In summary, we conducted an exome-chip association analysis and identified, for the first 
time, a highly significant association of a functional variant of GCKR, rs1260326 
(p.Pro446Leu), with circulating FGF21 levels, independent of obesity and other metabolic 
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traits. Our findings further highlighted the pleiotropic role of GCKR and provided insights 
into the regulation of FGF21 levels and its relationship with metabolic diseases. 
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Table 1. Clinical characteristics of subjects in the community-based and the two clinic-based cohorts. 
Variables CRISPS HKWDR P-value
†
 HK-CAD P-value
‡
 
N 1172 2884 - 1113 - 
Age 49.82 ± 10.68 60.87 ± 12.24 <0.001 67.32 ± 10.44 <0.001 
Sex (Male%) 43.7 59.1 <0.001 75.1 <0.001 
BMI (kg/m
2
) 24.02 ± 3.48 26.00 ± 4.27 <0.001 25.25 ± 3.65 <0.001 
T2DM (%) 12.8 100 <0.001 38.3 <0.001 
CAD (%) 0 36.7 <0.001 100 <0.001 
FGF21* (pg/mL) 154.72(83.90-266.80) 161.00(82.73-287.23) 0.237 241.38(149.71-376.50) <0.001 
Data as mean ± standard deviation or median with interquartile range. N: number; BMI: body mass index; CAD: coronary artery disease; T2DM: type 2 
diabetes; FGF21: fibroblast growth factor 21. CRISPS:  Hong Kong Cardiovascular Risk Factor Prevalence Study; HKWDR: Hong Kong West Diabetes 
Registry; HK-CAD: Hong Kong Chinese Coronary Artery Disease study. *Natural-log-transformed before analysis. †HKWDR versus CRISPS. ‡HK-CAD 
versus CRISPS.    
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Table 2. Variants associated with circulating FGF21 levels at P <1x10-5 in the combined analysis. 
A1: Minor allele; A2: Major allele; MAF: Minor allele frequency; SE: Standard error. CRISPS:  Hong Kong Cardiovascular Risk Factor Prevalence Study; 
HKWDR: Hong Kong West Diabetes Registry; HK-CAD: Hong Kong Chinese Coronary Artery Disease study. The betas are reported relative to the minor 
allele. *Model 1: Adjusted for age, sex, PC1 and PC2. 
†
Model 2: Adjusted for age, sex, BMI, PC1 and PC2. Chromosomal positions are presented according 
to human reference genome hg19. 
 
  
Community-based  Clinic-based  Combined 
(CRISPS; n=1172) (HKWDR; n=2884) (HK-CAD; n=1113) (CRISPS+HKWDR+HK-CAD; n=5169) 
    Beta   Beta   Beta    Beta   
Gene SNP Position A1/A2 (SE) P-value* (SE) P-value* (SE) P-value* MAF  (SE) P-value* P-value
†
 
GCKR rs1260326 2:27730940 T/C 0.22 3.31x10-8 0.13 5.19x10-7 0.06 0.184 0.455 0.14 1.61x10-12 3.01x10-14 
    (0.04)   (0.03)   (0.04)    (0.02)   
FTO rs17817964 16:53828066 T/C 0.09 0.139 0.14 1.42x10-4 0.16 7.01x10-3 0.158 0.13 1.44x10-6 7.59x10-5 
    (0.06)   (0.04)   (0.06)    (0.03)   
TSR1 rs2273983 17:2227988 C/T 0.69 3.55x10-3 0.45 8.27x10-4 0.37 0.127 0.009 0.48 4.61x10-6 4.90x10-6 
    (0.24)   (0.13)   (0.24)    (0.10)   
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Figure legend 
 
Figure 1. Quantile-Quantile plot.  
Quantile-Quantile plot of association P-values of all tested variants for FGF21 level. 
 
Figure 2.  Manhattan plot of the combined analysis association results. 
The y-axis represents the -log10 P value, and the x-axis represents the genomic position. The 
dots represent the 70,444 SNPs analyzed, relative to their position on each chromosome 
(alternating black and grey). The black horizontal dashed line indicates genome-wide 
significance (P =5x10
-8
). The diamond symbol indicates the most significantly associated 
SNP GCKR rs1260326 (p.Pro446Leu). 
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Supplementary notes 
Subjects 
All subjects of the current study were previously examined in the exome-array association 
studies of T2DM (1), blood lipid traits and CAD (2). Only those subjects who also had their 
blood samples available for measurement of circulating FGF21 levels were included in the 
present study. All participants gave written informed consent and the study protocol was 
approved by the Institutional Review Board of the University of Hong Kong/Hospital 
Authority Hong Kong West Cluster.  
 
(i) Community-based cohort:  
The Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS): The community-
based cohort included a total of 1172 Southern Han Chinese subjects from the Hong Kong 
Cardiovascular Risk Factor Prevalence Study (CRISPS) cohort (3), who were the non-CAD 
control subjects in our previous exome-chip association analysis on blood lipid traits and 
CAD (2). Details of the CRISPS cohort have been described previously (1; 2; 4). Briefly, 
CRISPS was first commenced as a population-based survey in 1995-1996. A total of 2895 
unrelated Chinese subjects were randomly selected by their telephone numbers from the 
Hong Kong population. All participants were invited to undergo a comprehensive baseline 
assessment of cardiovascular risks at the Queen Mary Hospital, Hong Kong. The subjects 
were then invited for subsequent prospective follow-up visits to assess for the development of 
major cardiovascular risk factors, in 2000-2004 (CRISPS2), 2005-2008 (CRISPS3) and 2010-
2012 (CRISPS4). The latest follow-up visit (CRISPS5) has been commenced in 2016. At 
each assessment, anthropometric and demographic were collected. The participants’ medical, 
treatment and family histories of the major cardiovascular risk factors were recorded by a 
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detailed questionnaire. Fasting venous blood were collected after an overnight fast for the 
measurement of glucose, lipids and biomarkers levels. FGF21 levels were measured in 
plasma samples collected at the second assessment (CRISPS2). A 75g oral glucose tolerance 
test (OGTT) was performed in all subjects who were not on treatment for diabetes.  
 
(ii) Clinic-based cohorts:  
The clinic-based cohort included a total of 3997 individuals recruited from the Hong Kong 
West Diabetes Registry (HKWDR) (5) and the Hong Kong Chinese Coronary Artery Disease 
(HK-CAD) study cohort (2), respectively.   
 
The Hong Kong West Diabetes Registry cohort (HKWDR; n=2884): The HKWDR was 
commenced in 2008. Participants of HKWDR were type 2 diabetes (T2DM) patients who 
were on regular follow-up at the medical specialist clinics of the Hong Kong West Cluster. 
The participants were invited to undergo comprehensive clinical assessments and laboratory 
investigations to determine the presence of chronic diabetic complications and their control of 
diabetes. The anthropometric and demographic data of the study subjects were collected at 
each assessment. The subjects’ medical, treatment and family histories of cardiovascular risk 
factors were recorded with a detailed questionnaire. Venous blood samples were drawn, with 
informed consent, after an overnight fast, for biochemical and DNA analyses. FGF21 levels 
were measured from the stored serum samples collected at the first assessment.  
 
The Hong Kong Chinese Coronary Artery Disease study cohort (HK-CAD; n=1113): The 
HK-CAD study cohort is an on-going prospective cohort study on the clinical outcomes and 
risk factors in Chinese patients with established CAD. This cohort was first initiated in the 
Queen Mary Hospital, Hong Kong, in 2004-2005. Briefly, consecutive patients who 
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underwent invasive coronary angiogram for assessment and treatment of CAD were screened. 
The severity of stenosis was determined by coronary angiogram. Patients who suffered from 
significant CAD with ≥50% stenosis in one or more of the epicardial coronary artery were 
invited to participate in this cohort. Detailed demographic and anthropometric data, such as 
major cardiovascular risk factors; and drug, family and medical histories were collected 
during their hospital admission or in the outpatient clinic follow-up. Blood samples were 
drawn from the participants after an overnight fast, with written informed consent, for 
biochemical and genetic analyses. FGF21 levels were measured from the plasma samples 
collected at recruitment.  
 
Measurement of circulating FGF21 levels  
Blood FGF21 levels of subjects were measured using a human FGF21 enzyme-linked 
immunosorbent assay (ELISA) kit according to the manufacturer’s protocol (Antibody and 
Immunoassay Services, University of Hong Kong) as previously described (6). Samples were 
diluted 1:1 before the assay was conducted. The 100ul diluted samples, calibrators, and 
quality controls were added to the 96-well microtiter plates coated with an affinity-purified 
polyclonal anti-human FGF21 antibody. A calibration curve was constructed by plotting the 
absorbance values at 450nm against FGF21 concentrations of the calibrators. The FGF21 
concentrations in the study samples were then determined by using the calibration curve. The 
intra- and inter-assay coefficients of variation of the FGF21 ELISA were 4 to 5% and 3.5 to 
10.2%, respectively. 
 
Quality control of genotype data 
Manual curation of genotype calls was conducted for over 55,000 variants which had a 
GenTrain score of less than 0.8; or with high missingness of greater than 1%; or were shown 
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to have poor genotype clustering in exome chip genotyping of more than 9000 subjects by 
our collaborators (7). A total of 4550 variants were excluded from further analysis due to 
poor genotype clustering. Individual-level quality control (QC) was conducted with regard to 
biological relatedness, duplication, gender mismatch, and possible sample contamination. For 
detection of possible existence of non-Chinese samples, a principal component (PC) analysis 
was conducted using a panel of >20,000 independent common SNPs (minor allele frequency 
[MAF] >0.05) with outliers removed from the analysis. A scree plot showing the 
eignenvalues, which represents the relative proportion of variance explained of the first 15 
principal components, is presented in Supplementary Figure 1. For SNP-level QC, variants 
with more than 2% missingness; or MAF of less than 0.1%; or showed significant deviation 
from Hardy-Weinberg Equilibrium (HWE) with P <1x10-5; or originally designed for the 
purpose of QC (e.g. fingerprint SNPs for sample tracking and grid SNPs for the identification 
of identity by descent segments) were excluded from the analysis. 
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Supplementary Figure 1. Scree plot 
 
 
 
 
 
 
 
 
 
 
A scree plot showing the amount of variation explained by the first 15 principal components 
(PCs). The first two PCs have shown statistical significance with P-values of less than 0.05 in 
the Tracy-Widom test. 
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Supplementary Figure 2. Regional plot  
 
 
 
 
 
 
 
 
 
 
 
 
The regional plot illustrating individual SNPs at the GCKR locus and their association to 
circulating FGF21 levels.  
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Supplementary Table 1. Index SNPs with Pcombined <5x10-4 in the combined analysis for association with FGF21 levels. 
 
      
Model 1   Model 2 
Gene SNP Position A1/A2 Annotation MAF Beta(SE) P-value  Beta(SE) P-value 
GCKR rs1260326 2:27730940 T/C p.Pro446Leu 0.455 0.14(0.02) 1.61x10-12  0.15(0.02) 3.01x10-14 
FTO rs17817964 16:53828066 T/C intronic 0.158 0.13(0.03) 1.44x10-6  0.11(0.03) 7.59x10-5 
TSR1 rs2273983 17:2227988 C/T p.Asn719Ser 0.009 0.48(0.10) 4.61x10-6  0.49(0.11) 4.90x10-6 
EARS2 rs200139797 16:23563485 C/T p.Met94Val 0.004 0.64(0.15) 1.69x10-5  0.64(0.15) 1.70x10-5 
GHRHR rs144372265 7:31009485 T/C p.Ala91Val 0.004 0.68(0.16) 2.90x10-5  0.62(0.17) 2.41x10-4 
MRPL33 rs3792252 2:27995931 A/G intronic 0.417 0.08(0.02) 3.83x10-5  0.07(0.02) 7.46x10-4 
C7 rs2271708 5:40936541 C/T p.Cys128Arg 0.033 0.22(0.05) 7.94x10-5  0.23(0.06) 6.61x10-5 
ENTPD4 rs190514217 8:23291891 T/C p.Asp521Asn 0.004 -0.58(0.15) 1.01x10-4  -0.55(0.15) 3.64x10-4 
MBNL2 rs7320865 13:97976442 G/A intronic 0.495 -0.08(0.02) 1.02x10-4  -0.07(0.02) 7.39x10-4 
CDH23 rs10999947 10:73434906 A/G p.Ser496Asn 0.305 -0.08(0.02) 1.33x10-4  -0.08(0.02) 1.36x10-4 
CETN3-MBLAC2 rs6890115 5:89721448 C/T intergenic 0.491 0.08(0.02) 1.52x10-4  0.08(0.02) 1.98x10-4 
RNF17 rs148232728 13:25433204 A/C p.Pro1226Thr 0.047 -0.17(0.05) 1.53x10-4  -0.16(0.05) 7.73x10-4 
ENPP3 rs6901900 6:132012886 G/T intronic 0.365 -0.08(0.02) 1.58x10-4  -0.08(0.02) 2.14x10-4 
DNAAF2 rs9989177 14:50092471 C/T p.Asp720Gly 0.129 0.11(0.03) 1.61x10-4  0.11(0.03) 1.58x10-4 
AKAP9 rs186148498 7:91731945 A/G p.Arg3712Gln 0.012 -0.35(0.09) 1.65x10-4  -0.34(0.09) 2.65x10-4 
XPO5 rs186877420 6:43519108 G/A p.Val552Ala 0.007 -0.45(0.12) 1.73x10-4  -0.47(0.12) 1.45x10-4 
LOC338758-LINC00615 rs535428191 12:90184174 A/C intergenic 0.002 0.77(0.21) 2.13x10-4  0.73(0.21) 4.43x10-4 
MIA3 rs77464975 1:222810206 G/C intronic 0.015 0.30(0.08) 2.22x10-4  0.28(0.08) 8.70x10-4 
OVOL1 rs77014695 11:65558702 G/T intronic 0.041 0.18(0.05) 2.27x10-4  0.19(0.05) 3.51x10-4 
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C6orf70 rs77857406 6:170160783 G/A p.Lys263Arg 0.010 0.36(0.10) 3.13x10-4  0.32(0.10) 2.31x10-3 
ARCN1 rs138250193 11:118461172 A/G p.Arg312Gln 0.010 0.36(0.10) 3.37x10-4  0.39(0.10) 1.45x10-4 
DUSP10-HHIPL2 rs17163128 1:222619902 T/C intergenic 0.241 0.08(0.02) 3.46x10-4  0.07(0.02) 1.57x10-3 
TNP1-DIRC3 rs12623324 2:218016330 G/A intergenic 0.221 -0.08(0.02) 4.10x10-4  -0.08(0.02) 1.66x10-3 
CUEDC1 rs17762338 17:55951037 T/C p.Arg169His 0.003 0.69(0.20) 4.47x10-4  0.70(0.20) 4.78x10-4 
OR13G1 rs147056410 1:247835749 T/C p.Ala199Thr 0.002 -0.82(0.24) 4.83x10-4  -0.83(0.24) 6.45x10-4 
MICALCL rs182486240 11:12348754 A/G p.Arg557Gln 0.005 -0.50(0.14) 4.93x10-4  -0.53(0.15) 3.82x10-4 
EDARADD rs60808129 1:236557804 A/G p.Glu20Glu 0.306 0.07(0.02) 4.97x10-4  0.08(0.02) 2.86x10-4 
A1: Minor allele; A2: Major allele; MAF: Minor allele frequency; SE: Standard error. The betas are reported relative to the minor allele. *Model 1: Adjusted 
for age, sex, PC1 and PC2. †Model 2: Adjusted for age, sex, BMI, PC1 and PC2. Chromosomal positions are presented according to human reference genome 
hg19. 
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